Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data

被引：1
|
作者：
Skrobo, D. [1 ]
Walsh, N. [2 ]
Quinn, C. [3 ]
Walshe, J. [4 ]
Smyth, L. M. [5 ]
Gullo, G. [4 ]
Crown, J. P. [4 ]
机构：
[1] St Vincents Univ Hosp, Dept Oncol, Dublin, Ireland
[2] Natl Inst Cellular Biotechnol, Sch Biotechnol, Dublin, Ireland
[3] St Vincents Univ Hosp, Pathol, Dublin, Ireland
[4] St Vincents Univ Hosp, Med Oncol, Dublin, Ireland
[5] St Vincents Univ Hosp, Dublin, Ireland
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [1] Clinical Characteristics of Long-term Survivors of Metastatic HER2+Breast Cancer
    Goldbach, Macy
    Burkbauer, Laura
    Keele, Luke
    Nazarian, Susanna
    Rothman, Jami
    Tchou, Julia
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S466 - S466
  • [2] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [3] Advances in anti-HER2 therapy in metastatic breast cancer
    Yao, Minya
    Fu, Peifen
    [J]. CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [4] Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series
    Takuwa, Haruko
    Tsuji, Wakako
    Yotsumoto, Fumiaki
    [J]. INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 52 : 125 - 131
  • [5] Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
    Kathrin Strasser-Weippl
    Nora Horick
    Ian E Smith
    Joyce O’Shaughnessy
    Bent Ejlertsen
    Frances Boyle
    Aman U Buzdar
    Pierre Fumoleau
    William Gradishar
    Miguel Martin
    Beverly Moy
    Martine Piccart-Gebhart
    Kathleen I Pritchard
    Deborah Lindquist
    Erica Rappold
    Dianne M Finkelstein
    Paul E Goss
    [J]. Breast Cancer Research, 17
  • [6] Long-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy
    Strasser-Weippl, Kathrin
    Horick, Nora
    Smith, Ian E.
    O'Shaughnessy, Joyce
    Ejlertsen, Bent
    Boyle, Frances
    Buzdar, Aman U.
    Fumoleau, Pierre
    Gradishar, William
    Martin, Miguel
    Moy, Beverly
    Piccart-Gebhart, Martine
    Pritchard, Kathleen I.
    Lindquist, Deborah
    Rappold, Erica
    Finkelstein, Dianne M.
    Goss, Paul E.
    [J]. BREAST CANCER RESEARCH, 2015, 17
  • [7] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Murthy, Pooja
    Kidwell, Kelley M.
    Schott, Anne F.
    Merajver, Sofia D.
    Griggs, Jennifer J.
    Smerage, Jeffrey D.
    Van Poznak, Catherine H.
    Wicha, Max S.
    Hayes, Daniel F.
    Henry, N. Lynn
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 589 - 595
  • [8] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Pooja Murthy
    Kelley M. Kidwell
    Anne F. Schott
    Sofia D. Merajver
    Jennifer J. Griggs
    Jeffrey D. Smerage
    Catherine H. Van Poznak
    Max S. Wicha
    Daniel F. Hayes
    N. Lynn Henry
    [J]. Breast Cancer Research and Treatment, 2016, 155 : 589 - 595
  • [9] Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer
    Lees, Caitlin
    Yazdan-Ashoori, Payam
    Jerzak, Katarzyna J.
    Gandhi, Sonal
    [J]. ONCOLOGIST, 2019, 24 (02): : E80 - E82
  • [10] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
12345